anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a tolnaftate-containing pharmaceutical for external use containing a water-soluble polymer compound, the tolnaftate, carboxyvinyl polymer, base and water, excellent in dispersibility with good feeling of use and capable of preventing crystals from depositing. CONSTITUTION:The objective substance obtained by subjecting a water-soluble polymer compound (e.g. hydroxypropyl cellulose) and tolnaftate to copulverizing treatment using an excipient (e.g. lactose) to prepare a fine powdery composition, adding a carboxyvinyl polymer, a basic substance (e.g. amines) and water to the resultant composition and, as necessary, adding additives, such as preservative or wetting agent, and preparing a pharmaceutical. The water-soluble polymer compound is used in an amount of >=0.1 pt.wt. based on the tolnaftate and the carboxyvinyl polymer is used in an amount of 0.1-5 pts.wt. based on the fine powdery composition. Thereby, the objective substance can be prepared without using a surfactant or organic solvent at all.
Esophageal cancer represents the seventh cause of cancer death in American men, and more than 90% of patients diagnosed with esophageal cancer will ultimately die of their disease. In the United States, 13,900 new cases of esophageal cancer and 13,000 deaths from esophageal cancer are anticipated in 2003 (Jemal et al, 2003). The lifetime risk of esophageal cancer is 0.8% for men and 0.3% for women (Ries et al, 2002). The risk increases with age, with a mean age at diagnosis of 67 years (Ries et al, 2002; Daly et al, 2000). Adenocarcinoma of the esophagus or gastroesophageal junction, a previously rare disease, is rapidly increasing in incidence in the United States and western countries and now accounts for more than half of newly diagnosed disease (Devesa et al, 1998).

Half of patients diagnosed with esophageal cancer present with overt metastatic disease, and chemotherapy is the mainstay of palliation in this setting. In patients who present initially with locoregional disease, the majority will eventually develop metastatic disease as well, with or without local recurrence of disease. Metastatic esophageal carcinoma is an incurable disease with median survival duration of 4 to 8 months. Combination chemotherapy, most often cisplatin-based, results in partial responses in 25% to 50% of patients with metastatic disease and rare complete responses, including a 35% response rate reported for the commonly used combination of cisplatin and fluorouracil (Ilson et al, 1996). Recent chemotherapy trials indicate an overlap in response rates for metastatic adenocarcinoma and squamous carcinoma carcinoma of the esophagus (Ilson et al, 1997). Responses to chemotherapy are generally short-lived, and toxicity of cisplatin-based chemotherapy, particularly in the palliation of metastatic disease, is often substantial and underscores the need to identify new agents in the treatment of esophageal carcinoma.
The invention discloses application of a traditional Chinese medicine composition to preparing medicine treating chronic stable angina pectoris. The composition is soft capsules prepared through a conventional preparation technology with ginkgo leaves, herba erigernotis, salviae miltiorrhizae, borneol, hawthorn fruits, gynostemma pentaphyllum, panax notoginseng and garlic as raw materials. The composition is prepared according to Miao medicine theories. The preparation is good in medicine component dissolution, high in bioavailability, little in dose and stable in drug property. The composition can be used for treating thoracic obstruction, breast pain, chest distress, hard breath, palpitation and the like caused by qi stagnation and blood stasis. The traditional Chinese medicine preparation has the functions of promoting blood circulation to remove blood stasis and tonifying qi and stopping pain.
Present invention provides a process to extract oil from Momordica cochinchinensis aril. Before the process, the aril can be added water and enzymes or added nothing. The process can be carried out with continuous centrifuge, such as horizontal centrifuge, butterfly centrifuge or tube centrifuge. Rotating speed is 2,000,5,000,10,000 and 20,000 RPM. Add water to aril ratio of 5:1, 7:1,10:1 or 20:1, water temperature is 25℃,50℃,80℃ or 98℃. Before the centrifugation process, the aril can be added other plant oil, the purpose is to reduce the concentration of pectin . Centrifugation times are 1,2 or 3, 100% pure Momordica cochinchinensis oil can be isolated. If the aril add plant oil, the product is mixed oil. Water-containing aril can be processed and used as 
by-products.
The invention is characterised in that tobacco compositions and their use and preparation method. The compositions of the present invention can based on kinds of processes. Described technique include film, tablet, profiled member, gel, can consumption unit, insoluble substrate and hollow shape. Outside smoke abatement grass, said composition also can comprise spice as described herein, colorant and other additives. Said composition is alternatively good to eat disintegrate. There has been described exemplary composition and their preparation method.
A high-fat diet (HFD) is associated with various adverse health outcomes, including cognitive impairment and an elevated risk of neurodegenerative conditions. This relationship is partially attributed to the influence of an HFD on the gut microbiota. The objective of this research was to evaluate the neuroprotective benefits of co-fermented black barley and quinoa with Lactobacillus (FG) against cognitive impairments triggered by an HFD and to investigate the microbiota-gut-brain axis mechanisms involved. C57BL/6J mice were randomized into four groups: the normal control group (NC, n = 10), the high-fat diet group (HFD, n = 10), the high-fat diet group supplemented with FG (HFG, 10 mL per kg BW, n = 10), and the high-fat diet group supplemented with Lactobacillus (HFL, 10 mL per kg BW, n = 10). Our results showed that the FG intervention enhanced the behavioral and locomotor skills of the mice, elevated the levels of dopamine (DA) and norepinephrine (NPI) in brain tissues, and alleviated synaptic ultrastructural damage in the hippocampus. Furthermore, FG intervention was observed to exert a protective effect on both the blood-brain barrier and the colonic barrier, as evidenced by an increase in the mRNA levels of Zona occludens-1 (ZO-1), Claudin-4, and Occludin in the hippocampus and colon. These beneficial effects may be attributed to FG's regulation of gut microbiota dysbiosis, which involves the restoration of intestinal flora diversity, reduction of the Firmicutes/Bacteroidetes (F/B) ratio, and a decrease in the levels of pro-inflammatory bacteria such as s_Escherichia coli E and g_Escherichia; moreover, there was an increase in the abundances of anti-inflammatory bacteria, such as s_Bacteroides thetaiotaomicron and s_Parabacteroides goldsteinii. Metagenomic analysis revealed that the FG treatment downregulated the lipopolysaccharide (LPS) pathway and upregulated neurotransmitter biosynthetic pathways. These probiotic effects of FG resulted in reduced production and "leakage" of LPS and decreased mRNA expression of Toll-like receptor 4 (Tlr4), cluster of differentiation 14 (CD14), and myeloid differentiation factor 88 (Myd88) in hippocampal and colon tissues. Consequently, a reduction was observed in the levels of inflammatory cytokines in the serum, hippocampus, and colon, along with suppression of the immunoreactivity of microglia and astrocytes. Our results suggest that FG may serve as an intervention strategy for preventing cognitive impairments caused by an HFD.
Participants will receive one tablet of the marketed reference formulation containing Eszopiclone 3mg. The tablet will be taken with water and in a fasting condition.
A container for use in the treatment and/or prophylaxis of viral infections and/or associated conditions is prefilled with a thixotropic gel characterized by a density of from about 1.02 to 1.095g/cm3. The container may be prefilled only with the gel, or may also comprise an anticoagulant, such as sodium citrate, or a coagulation activator, such as calcium gluconate. The container may be a centrifuge tube. A method for the preparation of a convalescent plasma comprises (a) centrifuging once only whole blood or bone marrow in a container or tube, where the tube is prefilled with a thixotropic gel having a density from 1.02 to 1.095 g/cm3. Optionally the method involves (b) homogenizing/resuspending the resulting composition from (a) and (c) collecting the convalescent plasma. The method may be used in the preparation of a convalescent plasma for use in the treatment of infectious conditions such as COVID-19.
The present invention provides methods, systems, and devices for displaying monitored activity data in substantially real-time on a screen of a computing device. An example method includes capturing, via an activity tracking device, motion data associated with user activity. Quantizing the motion data into a plurality of metrics associated with the user activity. The method stores the motion data in a storage of the activity tracking device. The method connects the activity tracking device with a computing device via a wireless data connection and transmits motion data to the computing device to display a metric, metrics on a graphical user interface of an activity application of the computing device. The sending of motion data to the computing device is configured to persist while additional motion data is captured and sent to the computing device. The metrics displayed on the graphical user interface are shown to change in incremental numerical or graphical form in substantially real-time.
A composition containing a fraction of Juniperus chinensis extract is provided to increase the expression of UCP2(uncoupling protein 2) or UCP3(uncoupling protein 3) and suppress insulin resistance. A composition for preventing and treating hyperlipidemia, fatty liver, diabetes or obesity comprises a fraction of Juniperus chinensis extract. The fraction of the chemical formula I is fraction solvent of porous absorbent and is obtained by treating a Juniperus chinensis with a mixture solevent of dichloromethane and methanol. The Juniperus chinensis is Juniperus chinensis var. sargentil, Juniperus chinensis var. globosa, Juniperus chinensis var. horizontalis, or santalini Lignum rubrum or the old pine tree. The porous absorbent is a silica, zeolite, active alumina, active carbon, agarose, dextran or cellulose. The fraction solvent has the weight ratio of dichloromethane:methanol in 99:1~60:40 The fraction is an epicedrol. The composition is pharmaceutical composition or food composition.
Placebo: Placebo saline solution (IV) q4w in combination with a second placebo saline solution (IV) q4w for up to 4 doses/cycles each, followed by a single placebo saline solution q4w. The first placebo saline solution monotherapy dose q4w will be 4 weeks after the final dose of the 2 placebo saline solutions in combination.
The invention discloses a tartaric acid sustained-release composition, and belongs to the technical field of cosmetics. The tartaric acid sustained-release preparation comprises the following components in percentage by weight: 2-30% of fruit acid, 5-55% of slow release agent and 15-93% of water. Wherein the fruit acid is one or more of glycolic acid, lactic acid, citric acid, tartaric acid, malic acid, salicylic acid, lactobionic acid, gluconic acid and mandelic acid; the slow release agent is a PEG and PPG polyether copolymerization compound. The invention also provides a preparation method and application of the tartaric acid sustained-release composition. Compared with the prior art, the invention has the beneficial effects that: the tartaric acid sustained-release composition has the characteristics of safety and no pain in user experience; meanwhile, the tartaric acid sustained-release composition is convenient to use, and can be freely used at home by a user without being operated by a professional. In addition, the tartaric acid sustained-release composition can obviously whiten and brighten the skin, remove dark yellow and fade color spots, and has better using effect.
A control circuit accesses a plurality of previously-optimized radiation treatment plans and also accesses a plurality of optimization precursor information items. Each of the latter corresponds to at least one of the plurality of previously-optimized radiation treatment plans. The control circuit then generates a machine learning model using the plurality of previously-optimized radiation treatment plans and the plurality of optimization precursor information items. By one approach, at least a majority of the plurality of optimization precursor information items originate with a given radiation treatment facility and not with an unrelated (physically or institutionally) facility. These teachings will accommodate use of any of a variety of optimization precursor information items. By one approach, at least some of the plurality of optimization precursor information items comprise clinical goals.
Participants with advanced GC/GEJ cancer and without DDR deficiency alterations as described above. Variants of unknown significance (VUS) of the DDR gene alterations are eligible. Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy, or in combination with other checkpoint inhibitors or other therapies.
The invention relates to a composition of catalpa extracts with functions of anti-mosquito and sun protection. It comprises 5-20wt% oil phase and 80-95wt% aqueous phase. The oil phase includes emulsifiers, UVB isolated agents and antioxidants, and the aqueous includes UVB/UVA isolated agents, UVA isolated agents, preservatives, catalpa extracts and solvents. Accordingly, it provides effective mosquito repellent effect by means of the nature catalpa extracts. It not only meets the trend of environmental protection, but also won't cause injuries or discomfort to users' bodies. Thus it solves the problem that the traditional Mosquito repellents with DEET ingredients are absorbed by human bodies to affect health. Relatively, it's safe in use.
PURPOSE:To obtain an intermediate condensate for the titled filler without irritation nor discoloration for a long period, by reacting a phenol with formaldehyde in the presence of sulfuric acid or zinc sulfate as a catalyst at a specific temperature, washing thoroughly the reaction product with water, and adding glucose thereto. CONSTITUTION:A mixture of a phenol, e.g. guaiacol, creosote or eugenol, with an alcohol-soluble vegetable fat or oil, e.g. castor oil, or an ester interchange material of the above-mentioned fat or oil is reacted with formaldehyde or a polymer thereof in the presence of sulfuric acid or zinc sulfate as a catalyst in the atmosphere of an inert gas under heating at 100-130 deg.C to give a thick malt syrup. The resultant thick malt syruplike polymer is then washed with water to 7pH, and an adequate amount of glucose is added thereto to afford an intermediate condensate. Calcium hydroxice alone or a composition, obtained by roasting a powder prepared by mixing the calcium hydroxide as a main component with an X ray contrast medium, and consisting essentially of calcium oxide is added to the above-mentioned condensate to give the aimed filler used for cutting living pulp.
From study entry through Week 1, participants received 5 mg of LDMTX once a week. For participants who were clinically stable at the Week 1 study visit, the dose of LDMTX was increased to 10 mg once a week through Week 12. For participants who were clinically stable at the Week 12 study visit, the dose of LDMTX was increased to 15 mg once a week through Week 24. Participants who did not meet the criteria for dose escalation were re-evaluated at the following study visit. In addition to LDMTX, all participants also received 1 mg of folic acid once a day from study entry throughout Week 24. After taking the final dose of LDMTX, all participants continued taking folic acid for an additional 4 weeks.
The knee osteoarthritis has high prevalence, which tends to increase with the aging population. The limited efficacy of pharmacological interventions stimulates the search for other options, in order to increase the therapeutic success. Acupuncture is widely used for pain control in several pathologies. A modality of intramuscular stimulation to quantify the intensity of the stimulus is electro acupuncture (EAC) that the intensity of 2 Hz accelerates the release of enkephalins, endorphins and beta-endorphins. The application of electric currents to modify brain function is a very old technique. The transcranial direct current stimulation (tDCS) is based on applying transcranial direct weak current (usually above 2mA) through electrodes in a non-invasive, simple and painless. Other advantages include low cost and the possibility of a placebo reliable. The purpose of this study is to evaluate the ability to reduce pain and improve functionality in chronic pain for knee osteoarthritis with two techniques, one that promotes a bottom-up approach (EAC) and other top-down (tDCS). We will seek to analyze the efficacy of them separately and together, seeking summation of results.
There is provided a modified antibody having an altered number of glycosylation sites as compared to the number in the equivalent natural antibody. Preferably the modified antibody is produced by recombinant DNA techniques involving the production of an expression vector containing a DNA sequence encoding a modified antibody chain having an altered number of glycosylation sites. The DNA sequence may be prepared from the natural antibody gene by site-directed mutagenesis. Preferably the modified antibody chain has an increased number of glycosylation sites; for instance a modified Fab, Fab' or (Fab')2? antibody with a glycosylation site introduced into the CL or CHl domain thereof. Altering the degree of glycosylation alters properties of the antibodies, e.g. blood clearance rate, when used $i(in vivo); generally the greater the degree of glycosylation the slower the blood clearance. The altered antibodies may be used for the preparation of compositions for use in diagnosis, e.g. $i(in vivo) diagnosis and imaging, or in therapy; glycosylation minus/reduced antibodies being preferred for diagnostic uses and glycosylation plus/increased antibodies being preferred for therapeutic application.
Postoperative folliculitis is a common complication after hair transplantation (HT) and requires effective preventive interventions. This study aimed to characterize postoperative folliculitis and determine the risk factors in patients underwent HT. The study was conducted at 4 clinical sites: Nanfang Hospital of Southern Medical University, the First Affiliated Hospital, Zhejiang University School of Medicine, the Affiliated Hospital of Guilin Medical University, and Peking University Third Hospital. Data of 1317 patients who had undergone HT and completed a 9-month follow-up from January 2018 to June 2021 were collected. The incidence of postoperative folliculitis and the patient demographics were assessed. Logistic regression analysis was used to identify the risk factors, and the characteristics of different types of folliculitis were compared.
* Healthcare professionals who prescribe Oral Transmucosal Fentanyl Citrate (OTFC) for outpatients must enroll in the TIRF REMS and comply with the requirements of the REMS to ensure safe use of OTFC [see Warnings and Precautions (5.7)].
  * Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5)]. Because the risk of overdose increases as opioid doses increase, reserve titration to higher doses of OTFC for patients in whom lower doses are insufficiently effective and in whom the expected benefits of using a higher dose opioid clearly outweigh the substantial risks.
  * It is important to minimize the number of strengths available to patients at any time to prevent confusion and possible overdose.
  * There is variability in the opioid analgesic dose and duration needed to adequately manage pain due both to the cause of pain and to individual patient factors. Initiate the dosing regimen for each patient individually, taking into account the patient's severity of pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse [see Warnings and Precautions (5.1)].
  * Respiratory depression can occur at any time during opioid therapy, especially when initiating and following dosage increases with OTFC. Consider this risk when selecting an initial dose and when making dose adjustments [see Warnings and Precautions (5)].
  * Instruct patients and caregivers to take steps to store OTFC securely and to properly dispose of unused OTFC as soon as no longer needed [see Warnings and Precautions (5.1, 5.3)].
  * Other TIRF formulations and OTFC are not equivalent. DO NOT substitute an OTFC prescription for any other TIRF formulation under any circumstances. Do not convert patients on a mcg per mcg basis from any other fentanyl product to OTFC [see Warnings and Precautions (5.5)].
This study aimed to identify biomarkers for chronic kidney disease (CKD) by studying serum metabolomics. Serum samples were collected from 194 non-dialysis CKD patients and 317 healthy controls (HC). Using ultra-high-performance liquid chromatography-tandem mass spectrometry (UPLC-MS), untargeted metabolomics analysis was conducted. A random forest model was developed and validated in separate sets of HC and CKD patients. The serum metabolomic profiles of patients with chronic kidney disease (CKD) exhibited significant differences compared to healthy controls (HC). A total of 314 metabolites were identified as significantly different, with 179 being upregulated and 135 being downregulated in CKD patients. KEGG enrichment analysis revealed several key pathways, including arginine biosynthesis, phenylalanine metabolism, linoleic acid metabolism, and purine metabolism. The diagnostic efficacy of the classifier was high, with an area under the curve of 1 in the training and validation sets and 0.9435 in the cross-validation set. This study provides comprehensive insights into serum metabolism in non-dialysis CKD patients, highlighting the potential involvement of abnormal biological metabolism in CKD pathogenesis. Exploring metabolites may offer new possibilities for the management of CKD.
BACKGROUND: Chronic systemic inflammation has been proposed as the underlying mechanism of pain chronicity in several pain conditions. In spite of the growing evidence supporting the role of systemic inflammatory markers as a diagnostic tool, their role has not been analyzed in a well-defined group of temporomandibular disorders (TMD) patients until now. This study aimed to investigate the association between various clinical features and comorbidity levels of TMD in relation to hematological markers and seek its association with long-term treatment response.
METHODS: Clinical features and hematological indices including those for systemic inflammation were assessed in TMD patients (n = 154). Examinations were re-done after 6 months of conservative treatment. Patients were divided into pain improved and unimproved groups based on ≥ 2 numeric rating scale improvement in pain intensity at 6 months for final analysis.
RESULTS: The portion of patients with low lymphocyte-to-monocyte ratio (p = 0.026), total protein (p = 0.014), hemoglobin (p = 0.040), and mean corpuscular hemoglobin concentration (p = 0.042) values showed significant differences according to prognosis groups. Low hemoglobin levels were significantly associated with unfavorable response to long-term treatment (β = 1.706, p = 0.018). High pre-treatment pain intensity (β=-0.682, p < 0.001) and low Graded Chronic Pain Scale (β = 1.620, p = 0.002) could predict significant pain improvement with long-term treatment.
CONCLUSIONS: Hematologic assessment could be considered in addition to clinical examination to better determine long-term prognosis in TMD patients.